Ferring Appoints Aaron Graff to Executive Board
June 02, 2017 11:45 KST
SAINT PREX, SWITZERLAND--(Business Wire/Korea Newswire) June 02, 2017 -- Ferring Pharmaceuticals announced today that Aaron Graff has been appointed Executive Vice President and Chief Commercial Officer and made a member of the Ferring Group Executive Board, effective immediately.
Aaron Graff joined Ferring in 2002 as Vice President Global Marketing, Business Development, and Medical Affairs, based in Copenhagen, Denmark. After leading the acquisition and integration of Israeli biopharmaceutical company BTG in 2005, he relocated his team to the newly established Ferring International Center in Saint-Prex, Switzerland, where he was promoted to Senior Vice President, Asia Region and Global Marketing. Since 2010, Graff has led Ferring’s U.S. operations from its U.S headquarters in New Jersey, first as Chief Operating Officer and since 2016 as Chief Executive Officer.
“Under Aaron’s leadership in the United States, our U.S. business grew at double-digit rates,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals. “His broad, global professional experience and track record make him uniquely qualified for this important role.”
Prior to joining Ferring, Graff worked at Bristol-Myers Squibb for over 17 years in a variety of sales, marketing and commercial operations management positions.
About Ferring Pharmaceuticals:
Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. A leader in reproductive and maternal health, Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative treatments to help mothers and babies, from conception to birth. The company also identifies, develops and markets innovative products in the areas of urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. For further information on Ferring or its products, visit www.ferring.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170601005645/en/
All releases from Ferring Pharmaceuticals
- Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical Trial Ever Conducted in Postpartum Haemorrhage
- Ferring Announces 30 Million CHF Investment in New Biotech Centre in Switzerland
- Ferring Announces Recipients of Innovation Grants Program 2017-2018
- Ferring enters into worldwide OmniAb® platform license agreement with Ligand
- Ferring and the Chinese Academy of Sciences Collaborate to Advance Research in Reproductive Medicine
Share this News Release
- 4,000media outlets
- 230industry fields